MMPs in ovarian cancer as therapeutic targets.

doi:10.2174/187152012802650174

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

MMPs in ovarian cancer as therapeutic targets.

Anti-cancer agents in medicinal chemistry - 1 Sept 2012

Karam Amer, Dorigo Oliver

Abstract excerpt

In the United States, about 22,000 women will be diagnosed with ovarian cancer in 2011, and an estimated 14,000 patients will succumb to the disease. Surgery and chemotherapy present the main treatment modalities, but despite the development of novel therapies, the overall 5 years survival for ovarian cancer patients with advanced disease at diagnosis remains at only about 30%. Novel therapeutic strategies are...

Topics

Antineoplastic Agents
Clinical Trials as Topic
Female
Humans
Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Molecular Targeted Therapy
Ovarian Neoplasms
Ovary
Peptidomimetics
Polymorphism, Single Nucleotide
Tetracyclines

Source

Open in PubMed

Identifiers

PMID: 22292752
DOI: 10.2174/187152012802650174

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics